BRIDGEWATER, N.J., May 06, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the first quarter ended March 31, 2021 and provided a corporate update. “Our sales organization continues to drive utilization of AMZEEQ and ZILXI, with prescriptions for both products gaining momentum,” said David Domzalski, Chief Executive Officer of VYNE Therapeutics. “During the first quarter, we unveiled our newest candidate FMX114, a combination topical gel product candidate for the treatment of mild-to-moderate atopic dermatitis. We plan to take FMX114 into a Phase 2a study in the third quarter, with top-line…

BRIDGEWATER, N.J., April 28, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the first quarter ended March 31, 2021, on Thursday, May 6, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Conference Call Details: Thursday, May 6th @ 8:30am Eastern Time Toll Free:  800-909-4985 International: 312-281-1211 Conference ID: 21993618 Webcast: http://public.viavid.com/index.php?id=144542 A replay of the call will be archived on the Company’s website at www.vynetherapeutics.com…

BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Barclays Global Healthcare Conference and H.C. Wainwright Global Life Sciences Conference. Presentation details can be found below. Barclays Global Healthcare Conference Day: Tuesday, March 9, 2021 Time: 8:00am Eastern Time Format: Fireside chat Webcast Link: https://kvgo.com/2021-global-healthcare-conference/vyne-therapeutics-2021     H.C. Wainwright Global Life Sciences Conference Day & Time: On demand, beginning 7:00am Eastern Time, Tuesday, March 9, 2021 Format: Fireside chat Webcast Link: https://journey.ct.events/view/7534c623-91e5-4fa6-9d64-6dbed8781b9a About VYNE Therapeutics Inc.VYNE’s mission is…

BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Barclays Global Healthcare Conference and H.C. Wainwright Global Life Sciences Conference. Presentation details can be found below. Barclays Global Healthcare Conference Day: Tuesday, March 9, 2021 Time: 8:00am Eastern Time Format: Fireside chat Webcast Link: https://kvgo.com/2021-global-healthcare-conference/vyne-therapeutics-2021     H.C. Wainwright Global Life Sciences Conference Day & Time: On demand, beginning 7:00am Eastern Time, Tuesday, March 9, 2021 Format: Fireside chat Webcast Link: https://journey.ct.events/view/7534c623-91e5-4fa6-9d64-6dbed8781b9a About VYNE Therapeutics Inc.VYNE’s mission is…

BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update. “We continue to make progress in the trial and utilization of our two commercially launched products, driving market share in the acne and rosacea categories,” said David Domzalski, Chief Executive Officer of VYNE. “Our R&D team has made significant strides in developing our investigational product pipeline, having successfully advanced FCD105, our minocycline-adapalene combination product candidate for moderate-to-severe acne, which we anticipate commencing a Phase…